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Uncontrolled TNF-α synthesis is known to play an important role in numerous 
inflammatory disorders, and multiple transcriptional and post-transcriptional regulatory 
mechanisms have therefore evolved to dampen the production of this important pro-
inflammatory cytokine. By examining the anti-inflammatory properties of the vitamin B3 
constituent nicotinamide, we have uncovered a novel regulatory pathway controlling TNF-α 
production. Exogenous nicotinamide inhibits TNF-α secretion through modulation of mRNA 
translation efficiency. Moreover, the capacity to produce TNF-α appears to be directly 
correlated with intracellular NAD levels, suggesting that a NAD-dependent biological event 
that can be inhibited by nicotinamide controls TNF-α synthesis in cells of the immune 
system. Sirtuins represent NAD-dependent deacetylases involved in regulation of gene 
expression in both mammals and yeasts, and are known to be inhibited by nicotinamide. We 
demonstrate herein that similarly to nicotinamide, structurally unrelated sirtuin inhibitors 
downregulate TNF-α secretion with minimal effect on TNF-α gene transcription. By over-
expressing individual sirtuin members in cell lines transiently expressing TNF-α, we have 
identified SIRT6 as a sirtuin member able to upregulate TNF-α synthesis in vitro. In 
agreement with this finding, bone-marrow derived dendritic cells from SIRT6 KO mice 
display reduced TNF-α synthesis in response to CpG. Collectively, these data delineate a 
novel relationship between metabolism and the inflammatory response, by uncovering the 





Nicotinamide adenine dinucleotide (NAD) is an essential coenzyme regulating 
numerous cellular metabolic pathways. In the last few decades, a growing number of studies 
have uncovered an additional, nonredox function of NAD in cellular physiology. In particular, 
NAD has been recognized as a substrate for a growing group of “NAD–dependent” enzymes 
with multiple roles in cellular regulation 1. NAD-dependent protein modifications are 
catalyzed by enzymes broadly defined as ADP-ribosyl transferases. Two enzyme families, 
known respectively as mono-ADP-ribosyltransferases (mARTs) and poly(ADP-ribose) 
polymerases (PARPs) have in particular been recently identified in mammals. mARTs 
represent a family of ectoenzymes including GPI-anchored membrane proteins and secreted 
forms, while PARPs (comprising 18 members to date 2) are intracellular proteins usually 
located within the nuclear compartment. NAD also represents a substrate for members of a 
third evolutionarily conserved family of proteins collectively known as “sirtuins” 34. These 
proteins, (for which seven members, SIRT1 to SIRT7 have been described) regulate a wide 
range of biological processes including gene silencing 5, aging 67, cell survival in response to 
stress 8 9, cell differentiation 10 and metabolism 1112. The founding member of this family, Sir2 
in yeasts and its mammalian homologue SIRT1, catalyzes a unique reaction in which the 
cleavage of NAD and the deacetylation of substrate are coupled to the formation of O-acetyl-
ADP-ribose 13  
A common feature of all these “NAD-dependent” enzymes is the cleavage of the 
ADP-ribose moiety of NAD with the concomitant release of nicotinamide (NAm), which 
therefore serves as an endogenous end product inhibitor 14. NAm, in conjunction with 
nicotinic acid, also represents an essential vitamin (Vitamin B3 or niacin) required as an 
exogenous precursor of NAD in most living organisms 15. Collectively, these observations 
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have shifted interest in NAm from a simple nutrient (NAD precursor) to a pharmacological 
agent able to interfere with NAD-consuming enzymes. It is therefore presently believed that 
intracellular NAD and NAm levels may regulate numerous cellular reactions by modulating 
the activity of a large number of NAD-dependent enzymes 16.  Recently, experiments 
performed in yeasts support this contention, and suggest an important role for the NAm/NAD 
ratio in regulating several biological processes 17. 
Our own interest in the potential link between NAD biosynthesis and cell regulation 
derives from studies performed in immune cells that led to the identification of the gene 
encoding for the murine nicotinamide phosphoribosyltransferase (NAmPRT, EC 2.4.2.12) 18. 
This enzyme catalyzes the first step of the salvage pathway allowing NAD biosynthesis from 
NAm. NAmPRT levels were found upregulated upon stimulation of immune cells both in vivo 
and in vitro 1920. Although elevated NAmPRT expression may simply represent a 
physiological response to meet the demand for increased metabolic resources in 
activated/proliferating cells, it may also represent a regulatory mechanism providing adequate 
intracellular NAD levels required for the effector function of one or several NAD-consuming 
enzymes important for immunoregulation.   
Several lines of experimental evidence support a functional link between NAD 
metabolism and inflammation. NAm has been shown to inhibit the production of key 
inflammatory mediators such as NO 21 and cytokines 22 23. These observations have been 
generally interpreted in light of the recently uncovered role of PARP-1, in the regulation of an 
inflammatory response 24. Indeed (i) PARP-1 has been shown to act as a transcriptional 
activator of NF-kB 25 (ii) NAm and other structurally unrelated pharmacological PARP-1 
inhibitors are of remarkable therapeutic efficacy in experimental models of inflammatory-
related diseases 24 and finally (iii) PARP-1 -/- mice are protected from endotoxic shock 26,27. 
These and other observations engendered the view that PARP-1 may represent the molecular 
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link between NAm, NAD biosynthesis and secretion of pro-inflammatory cytokines through 
regulation of NF-kB transcriptional activity.  
The purpose of the present study was to evaluate the functional link between NAD 
metabolism and inflammation. The observations described in this study indicate a contrasting 
role for NAm and NAD in regulating the secretion of TNF-α. While adequate intracellular 
NAD levels are required for optimal TNF-α production, exogenous NAm inhibits TNF-α 
suggesting an important role for a NAD-dependent, NAm-inhibitable enzymatic activity in 
regulating the production of this potent pro-inflammatory mediator. However, and in contrast 
to a prevailing view, NAm appears to exert its anti-inflammatory properties in a PARP-1-
independent fashion. Using a set of structurally unrelated pharmacological inhibitors and a 
genetic approach, we identify herein an important role for SIRT6, a member of the sirtuin 




NAm protects mice against an endotoxic shock.  
A well defined model of acute septic shock was used to evaluate the anti-inflammatory 
properties of NAm in vivo. Groups of mice were injected with a lethal dose of LPS (20 
mg/kg) in combination with either saline or NAm (500 mg/kg) at various times before or after 
endotoxin administration. As shown in Figure 1A, NAm was found to protect mice against a 
lethal high dose of LPS even when injected 2 hours following endotoxin challenge.  
D-galactosamine (D-Gal) sensitizes animals to LPS by causing severe liver damage 
secondary to TNF-induced hepatocyte apoptosis. As shown in Figure 1A, NAm protected D-
gal sensitized mice against an LPS, but not against a TNF-α challenge, indicating that this 
vitamin did not affect the late stages of the biological response to endotoxemia, but rather 
interfered with an early event of the inflammatory response, as confirmed by the analysis of 
the peak response of several cytokines released in the serum of treated animals. NAm 
administration led to a notable shift in the cytokine response, with marked reduced levels of 
TNF-α and IL-12, and increased levels of the anti-inflammatory cytokine IL-10 (Figure 1B). 
Since endogenous IL-10 is known to modulate the secretion of pro-inflammatory mediators 
during LPS challenge in vivo 28, we repeated these experiments in mice genetically deficient 
for IL-10. As shown in Figure 1C, NAm failed to inhibit IL-12 secretion in the absence of 
endogenous IL-10, while it strongly reduced LPS-induced, serum TNF-α levels in both mouse 
strains. To further confirm that NAm inhibited TNF-α production in an IL-10-independent 
fashion, wt animals were injected with a combination of blocking antibodies to IL-10 and IL-
10R before LPS challenge. As expected, in vivo blocking of IL-10 signalling led to enhanced 
TNF-α secretion that however retained sensitivity to the inhibitory effects of NAm (Figure 
1C). Finally, based on the ability of NAm to inhibit PARP-1 enzymatic activity (with an IC50 
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in the 30 µM range 29), we wished to examine the potential role of PARP-1 in mediating the 
anti-inflammatory properties of this vitamin. PARP-1 KO mice responded to LPS challenge 
by secreting control levels of serum TNF-α and were equally sensitive to the anti-
inflammatory properties of NAm both in vivo and in vitro (Figure 1D). Collectively, these 
observations are best explained by assuming that the anti-inflammatory properties of NAm 
are due to the ability of this vitamin to block TNF-α secretion by activated cells in a PARP-1 
independent fashion.  
 
 
NAm inhibits TNF-α synthesis at the post-transcriptional level.  
To better understand the mechanisms by which NAm affects TNF-α production, the 
well described mouse RAW264.7 macrophage cell line was used as responder cell. TNF-α 
secretion by LPS-stimulated RAW 246.7 was inhibited by exogenous NAm with minimal 
effect on mRNA accumulation (Figure 2A). mRNA stability was not or only marginally 
inhibited by NAm, suggesting that this vitamin inhibited TNF-α protein production by 
interfering with a  post-transcriptional step (Figure 2A). To further support this contention, 
RAW 246.7 cells were stimulated with LPS for 2 hours, washed, and subsequently incubated 
in the presence of media or graded doses of NAm for an additional 30 minutes. Again, NAm 
strongly inhibited TNF-α protein secretion, with minimal effect on TNF-α transcripts as 
judged by ELISA and northern blot analysis, respectively (Figure 2B). Cytoplasmic extracts 
from LPS or LPS/NAm treated cells were than fractionated over sucrose gradients and TNF-α 
mRNA quantified by northern blot. LPS treatment led to the typical accumulation of TNF-α 
mRNA in the polysome containing, heavy fraction of the gradient (Figure 2C, fractions 10 to 
13). NAm decreased the proportion of TNF-α transcripts that associate with polysomes, 
concomitant with a shift towards fractions containing smaller polysomes and monosomes 
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(Figure 2C, fractions 1 to 4). Polysome containing GaPDH mRNA display the same profile in 
both control, and NAm-treated cells (Figure 2C, right panel). Finally, RAW 264.7 cells were 
incubated in medium containing radioactive amino acids and the synthesis of TNF-α in 
response to LPS was followed by immunoprecipitation and polyacrylamide gel 
electrophoresis. As shown in Figure 4C, NAm significantly reduced the accumulation of 
TNF-α protein in cell extracts, in keeping with the conclusion that it affected the translation 
efficiency of TNF-α mRNA.  (Figure 2D). To eliminate any possible interference of NAm 
with the TLR signalling cascade regulating gene transcription and mRNA splicing, the human 
293T cell line was transiently transfected with constructs expressing the complete human 
TNF-α cDNA or the murine IL-2 ORF under the control of a viral (CMV) promoter. As 
shown in Figure 2E, NAm selectively inhibited TNF-α secretion in this experimental setting 
with minimal effect on IL-2 production, strongly suggesting that it did not interfere with the 
general transcriptional or translational machinery. Finally, an ELISA assay detecting both 
soluble and cell-associated forms of TNF-α was used to exclude any interference of this 
vitamin with the intracellular traffic or maturation of the high molecular weight, 
transmembrane form of the TNF-α precursor protein. NAm inhibited TNF-α protein 
accumulation in this assay, confirming the inhibitory effect of NAm on TNF-α protein 
synthesis (Supplementary Fig. 1). Collectively, these observations suggest a role for NAm 
modulating the translational efficiency of TNF-α mRNA 
To evaluate the effect of exogenous NAm on TNF-α protein synthesis in a more 
physiological setting, freshly isolated, splenic murine dendritic cells were used in vitro as 
responder cells. These cells respond to microbial stimulation by undergoing a complex 
biological response (referred to as maturation) characterized by secretion of pro-inflammatory 
soluble mediators (cytokines and chemokines) and upregulation of cell surface markers 
including the co-stimulatory ligands/receptors CD40, CD80, CD86 and MHC class II. In 
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keeping with previous observations, exogenous NAm inhibited TNF-α synthesis  in response 
to CpG  without affecting the capacity of these cells to secrete the chemokine RANTES 
(Figure 3A) or to upregulate CD40, CD80, CD86 and MHC class II molecules expression 
(Figure 3B). Noteworthy, and in keeping with previous studies, NAm preferentially affected 
protein synthesis over mRNA accumulation, as shown in Figure 3C.  
 
Endogenous NAD levels determine TNF-α protein synthesis efficacy. 
Since NAm represents an endogenous feedback inhibitor of all NAD-dependent 
enzymes described to date, the previous observations suggest an important role for a NAD-
dependent enzyme in regulating TNF-α protein synthesis. To directly evaluate this possibility, 
we designed an experiment aimed at manipulating the intracellular NAD levels in a TNF-α 
producing cell line. Eukaryotic cells can synthesise NAD from four distinct precursors 
including the amino acid tryptophan, the niacin (vitamin B3) components nicotinic acid (NA) 
and nicotinamide (NAm) and finally the recently identified intermediate nicotinamide 
riboside (NR 30, see Supplementary Fig. 2). It is noteworthy that only hepatocytes express 
high levels of tryptophan 2,3 dioxygenase 15 (TDO, EC 1.13.11.11), the first enzyme of the 
enzymatic pathway leading to NAD biosynthesis from tryptophan, indicating thus that most 
cells in the organism are dependent upon exogenous niacin (NAm or NA) for NAD 
biosynthesis. The human THP-1 macrophage cell line has been shown to express both 
nicotinamide phosphoribosyltranferase (NAmPRT, EC 2.4.2.12) and nicotinic acid 
phosorphorybosyl transferase (NAPRT, EC 2.4.2.1) rendering this cell line able to use both 
niacin components as NAD precursors31. Since conventional media formulations do not 
contain nicotinic acid nor nicotinamide riboside, NAm represents the only NAD precursor 
available under standard culture conditions (e.g. 8µM in RPMI and 33µM in DMEM). 
Moreover, NAD biosynthesis from NAm can be specifically inhibited by APO866, a recently 
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described and potent low molecular weight inhibitor of NAmPRT (with no effect on NAPRT 
32) with an IC50 in the nM range 31. THP-1 cells were incubated in control media (containing 
NAm as sole NAD precursor), or in media supplemented with graded doses of APO866. As 
expected, APO866 was able to strongly inhibit intracellular NAD concentrations upon 
overnight incubation with an approximate IC50 of 0.1 nM (Figure 4A). This decrease in 
intracellular NAD levels was mirrored by a reduced capacity to produce TNF-α in response to 
LPS (Figure 4A). Exogenous nicotinic acid (NA) restored intracellular NAD levels in 
APO866-treated cells, and concomitantly allowed control-level TNF-α secretion in response 
to LPS despite continuous exposure to the NAmPRT inhibitor (Figure 4B). Similarly, addition 
of nicotinamide mononucleotide (NMN), the product of the NAmPRT-catalyzed reaction (see 
Supplementary Fig. 2), restored both intracellular NAD levels and TNF-α production in THP-
1 cells, confirming both the specificity of action of APO866 and the role of intracellular NAD 
in regulating TNF-α production (Figure 4C). Accordingly, culture of THP-1 cells in the 
presence of an exogenous source of NA led to a striking increase in intracellular NAD levels 
(400 % increase when compared to control cells) and supra-optimal TNF-α secretion capacity 
(Figure 4D). Note that neither APO866 nor NAD precursors affected cell viability in this 
experimental setting (not shown). Collectively, these observations establish a close 
relationship between intracellular NAD levels and control of TNF-α synthesis.   
 
SIRT6 regulates TNF-α production.  
The previous observations suggested that TNF-α protein synthesis was under the 
control of a NAD-dependent, NAm-sensitive biological event. Recently, studies mostly 
performed in yeasts have identified sirtuins as important sensors of intracellular NAD and 
NAm levels, providing a molecular link between energy metabolism and signalling mediated 
by this family of NAD-dependent enzymes. Since TNF-α protein synthesis appeared to be 
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under the positive and negative control of respectively NAD and NAm, we hypothesized that 
one or multiple members of the sirtuin family could exert a positive control on TNF-α 
production. To evaluate this hypothesis, murine dendritic cells and cell lines were incubated 
in the presence of a panel of structurally unrelated sirtuin inhibitors 33,34 and stimulated by 
CpG. All sirtuin inhibitors led to a marked reduction in TNF-α protein secretion, with 
minimal effect on RANTES synthesis and on expression of cell surface associated markers 
(Figure 5A). Similar observations have been performed using other responder cells lines and 
an additional sirtuin inhibitor (dyihydrocoumarin 35, data not shown). These observations 
suggest a role for a sirtuin member in regulating the efficacy of TNF-α synthesis in response 
to microbial stimulation, and led us to evaluate the possible anti-inflammatory properties of 
cambinol, known to display reduced toxicity in vivo 34, in a mouse model of acute septic 
shock In keeping with the in vitro data, cambinol displayed anti-inflammatory properties in 
vivo, as shown by its ability to significantly inhibit TNF-α secretion in response to acute LPS 
injection (Figure 5B). Note that RANTES synthesis in vivo was used as a control for possible 
non specific effect of the drug on the innate immune response. Finally, and in keeping with 
previous observations related to NAm, reduction of intracellular NAD levels and incubation 
in the presence of sirtuin inhibitors appeared to inhibit TNF-α protein synthesis with minimal 
effect on mRNA accumulation (see Supplementary Fig. 3). 
To positively identify the sirtuin member regulating TNF-α translation efficiency, we 
constructed plasmids encoding all murine sirtuins and transiently co-transfected them with a 
hTNF-α expression vector and a murine IL-2 reporter vector (included to normalize for 
extract concentrations, transfection efficiency and overall translation status) in the 293T 
human cell line. Despite some variations, all transfected cells lines expressed the 
corresponding sirtuin member as shown in Figure 6A. Analysis of the relative expression of 
TNF-α vs IL-2 proteins in the supernatants of transfected cells lines revealed a positive 
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influence of SIRT6 on TNF-α protein synthesis in this experimental setting (Figure 6B). 
Since none of the mitochondrial (SIRT3, SIRT4 and SIRT5) or predominantly cytoplasmic 
(SIRT2) sirtuins (Figure 6B) affected TNF-α secretion in this assay, they were excluded from 
further analysis. The effect of nuclear sirtuins on TNF-α expression was analyzed in more 
details, as shown in Figures 6C and 6D. In this experiment, cells were transiently transfected 
with plasmid encoding wild type or catalytically inactive mutant versions of SIRT1, SIRT6 
and SIRT7, and translational efficiency evaluated following a previously described approach 
36 by comparing TNF-α and IL-2 mRNA levels to their protein counterpart. Overexpression 
of SIRT6 consistently resulted in increased TNF-α protein secretion relative to its mRNA 
levels (Figure 6D). In keeping with the pharmacological studies, the ability of SIRT6 to 
augment TNF-α translation efficiency required its enzymatic activity, since a mutant SIRT6 
construct lacking enzymatic activity (data not shown) was unable to affect TNF-α production 
(Figure 6D). Finally, to confirm the role of SIRT6 in regulating TNF-α synthesis, bone 
marrow-derived dendritic cells from wt and SIRT6 KO mice 37 were stimulated in vitro with 
CpG and supernatants tested for TNF-α content. Lack of SIRT6 expression decreased the 
capacity of BMDC to produce TNF-α, confirming the role of this sirtuin member in 




Inflammation represents an essential host response to microbial challenge, allowing 
the recruitment and activation of leukocytes at the site of infection 38. Infection-mediated 
autoagression may however subsides even as the offending agents have been eliminated, 
stressing the importance of fine tuning the inflammatory response to achieve the appropriate 
level and duration of the response 39. Inadequate production of TNF-α is involved in 
numerous pathological situations 40 such as diabetes, Crohn’s disease and rheumatoid arthritis. 
Accordingly, numerous studies have revealed that expression of TNF-α is tightly controlled, 
both transcriptionally and post-transcriptionally by modulation of mRNA stability and 
translational efficiency 41.  
The present study uncovers a close relationship between NAD metabolism and 
production of TNF-α, identifying a novel regulatory pathway controlling TNF-α synthesis by 
cells of the immune system. We demonstrate in this report that the TNF-α translation 
efficiency requires adequate intracellular NAD levels and is inhibited by exogenous NAm, 
revealing a potentially important link between cellular metabolites and inflammation.  
The anti-inflammatory properties of NAm have been known for decades 22. However, 
despite the longstanding interest in the pharmacological properties of this vitamin, the 
mechanisms by which it affects an inflammatory response have not been clearly established. 
One the major difficulties in interpreting the biological properties of NAm relates to its wide 
range of putative targets 42. In general, the anti-inflammatory properties of NAm have been 
attributed to its ability to inhibit PARP-1, but experiments described herein (see Figure 1) and 
performed by others 23,27 fail to support this hypothesis.  Studies performed mostly in yeasts 
have led to consider members of the sirtuin family as important sensors of the intracellular 
NAm / NAD status 43 44 45. The present work concurs with this hypothesis and suggest a link 
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between NAD metabolism, sirtuin activity and regulation of TNF-α secretion. Experiments 
performed using APO866 (a potent inhibitor of the salvage pathway of NAD biosynthesis 
from NAm 31) and exogenous NAD precursors demonstrate a clear link between intracellular 
NAD levels and TNF-α production.  All sirtuin inhibitors tested in this study (and 
encompassing structurally distinct molecules such as NAm, sirtinol and cambinol) displayed 
similar pharmacological properties in vitro, inhibiting TNF-α synthesis at a post-
transcriptional step (see Supplementary Fig. 3) with minimal effect on RANTES secretion and 
expression of cell surface markers induced upon stimulation (Figures 3 and 5). To further 
strengthen the central role of sirtuins in sensing intracellular NAD levels in this model, we 
have been able to demonstrate the ability of APO866 to both reduce intracellular NAD levels 
(see Figure 4) and to modulate the activity of SIRT1 in a cellular model, as described in 
Supplementary Figure 5. Briefly, APO866 treatment led to the accumulation of the acetylated 
form of p53, a well known target for SIRT1 46. The first strategy that was used to identify the 
sirtuin member involved in TNF-α synthesis was based on a lentiviral-mediated short hairpin 
RNA system to individually knockdown all seven members of the sirtuin family. Although 
expression of each target gene was moderately suppressed using this approach, it did not lead 
to a reproducible and significant reduction in TNF-α synthesis (not shown). We therefore 
developed an in vitro assay allowing us to evaluate the effect of each sirtuin member on TNF-
α synthesis. SIRT6 was the only sirtuin member found to positively regulate TNF-α secretion 
when co-transfected with a TNF-α encoding plasmid. In keeping with our pharmacological 
observations, a mutant form of SIRT6 lacking enzymatic activity 47 37 was found ineffective in 
this assay (see Figure 6). The role of SIRT6 in regulating TNF-α production was further 
confirmed using inflammatory cells derived from SIRT6 KO mice (Figure 6D). Note however 
that an in depth analysis of the role of SIRT6 in vivo awaits the development of a mouse strain 
expressing a conditional allele of SIRT6, since SIRT6 KO mice display multiple phenotypic 
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abnormalities including uncontrolled cell death and an altered immune system that may non-
specifically affect an inflammatory response in vivo 37.  
Similarly to other sirtuin members, SIRT6 expresses both an ADP-ribosyltransferase 
and protein deacetylase activity, although the physiological substrates for these enzymatic 
reactions remain to be determined 37. In addition, SIRT6 is predominantly nuclear and further 
experiments are therefore warranted using cells of the immune system to evaluate a possible 
cytoplasmic location of this protein compatible with a role in translational regulation. Based 
on the observations reported herein, we would suggest a role for SIRT6 in a NAD-dependent, 
post-translational modification of a cellular substrate involved in regulation of the 
translational efficiency of selected mRNAs.  
The present studies may also contribute to a better understanding of the in vivo 
pharmacological properties of NAm. NAm represents a potentially valuable pharmacological 
agent due to its low cost, non-proprietary status and well established safety profile in humans. 
The present study raises however some concern about its efficacy in vivo as an anti-
inflammatory compound. Indeed, NAm represents both a feedback inhibitor of NAD-
consuming reactions and an endogenous NAD precursor. As such, NAm can both inhibit and 
promote the enzymatic activity of NAD-requiring enzymes depending on dosage and timing 
of administration. Thus, while high doses of NAm in vivo inhibit TNF-α secretion when 
injected 1 hour before a microbial stimulus, they could in fact increase an inflammatory 
response at a later stage, by replenishing the intracellular NAD pool on immune cells. 
Collectively, these studies highlight the possible "double-edged sword" type of response 
induced by NAm in vivo, with both beneficial and detrimental effects on the inflammatory 
response depending on dose and treatment duration. 
In marked contrast, the possibility to selectively inhibit sirtuin activity in vivo without 
altering the intracellular NAD status may represent a novel and promising strategy for treating 
 16
inflammatory disorders. APO866 has been shown to represent a potent NAmPRT inhibitor 
with limited toxicity in vivo 31. Acute administration of this compound in vivo significantly 
inhibits TNF-α secretion in response to LPS (see Supplementary Fig. 5 and Busso et al, 
submitted for publication). Similarly, chronic treatment with this compound has been recently 
shown to protect mice against a collagen-induced arthritis, confirming the possibility to 
inhibit an inflammatory response in vivo by modulating NAD metabolism (Busso et al, 
submitted for publication). Based on the evidence provided herein, sirtuin inhibitors may 
represent novel valuable drug candidates. Most inhibitors available to date appear to affect the 
enzymatic activity of multiple sirtuin members and further studies are therefore warranted to 
identify a specific SIRT6 inhibitor able to modulate an in vivo inflammatory response.  
In conclusion, the present study provides a novel example of “chemomodulation” in a 
complex organism, a mechanism whereby small-molecule metabolites involved in “energy 
metabolism” act as molecular regulators of gene expression, and paves the way to novel anti-






Mice and in vivo experiments. C57BL/6 mice, were purchased form Harlan (Nederland). All 
mice were bred in our pathogen-free facility and used at 6–9 weeks of age. All experiments 
were performed in compliance with the relevant laws and institutional guidelines and have 
been approved by the local committee from the Institut de Biologie et Médecine Moléculaires 
from the Université Libre de Bruxelles (Gosselies, Belgium). IL-10 knockout mice were 
purchased from Jackson Laboratories (Bar Harbor, Maine). PARP-1 knockout mice were 
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kindly provided by Dr. G. de Murcia (Ecole Supérieure de Biotechnologie de Strasbourg, 
Illkirch, France). Mice were injected intravenously (i.v.) into the lateral tail vein or 
intraperitoneally (i.p.) with indicated doses of LPS from E. coli (serotype 0111:B4), NAm 
(both from Sigma, St Louis, MO), APO866 (previously identified as FK866 31 was 
synthesized and provided by Astellas Pharma GmbH, Munich, Germany) or Cambinol. 
Control animals were injected with the same volume of PBS or solvent. NAm, LPS, D-
galactosamine (D-gal, Sigma), TNF-α (eBioscience, San Diego, CA) and the IL-10 antibodies 
cocktail (anti-IL-10R mAb 1B1.2, anti-IL-10 mAb JES5-2A5, produced in our own 
laboratory) were diluted in pyrogen-free saline and injected as described.  
 
Purification of dendritic cells. Splenic dendritic cells were purified as follows. Mice were 
injected s.c. with 106 B16 melanoma cells engineered to stably produce murine Fms-like 
tyrosine kinase 3 48 and spleens were harvested 9 days later. Spleen cells were digested with 
collagenase type 3 (Worthington Biochemicals, New Jersey, USA), further dissociated in 
Ca2+-free medium, and separated into low and high density fraction on a Nycodenz gradient 
(Nycomed, Oslo, Norway). The low density fraction was separated according to CD11c 
expression by incubation with anti-CD11c–coupled microbeads followed by one passage over 
a MACS column (Miltenyi Biotec, Bergisch-Gladbach, Germany). The CD11c-positive cells 
were cultured in RPMI 1640 containing 2% Ultroser HY (Life Technologies, Paisley, 
Scotland), and were induced to mature during overnight culture in the presence of the 
indicated dose of CpG-ODN 1826 (Eurogentec, Belgium). Bone marrow-derived dendritic 
cells (BMDC) were generated as follows. Frozen bone marrow cells were plated at 2x105 
cells/ml in medium supplemented with 10 ng/ml GM-CSF in 6-well plates in a volume of 6 
ml. At days 3 and 6, 4 ml of supernatant was replaced by 4 ml of fresh medium containing 
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GM-CSF. At day 9, cells were collected, centrifuged and resuspended in fresh medium in the 
presence of the indicated dose of CpG-ODN. 
 
Antibodies and Cytofluorometric analysis. Purified DCs were analyzed by flow cytometry 
with a FACSortTM (Becton Dickinson). The cells were labeled with PE-coupled N418 (anti-
CD11c), 3/23 (anti-CD40), 16–10A1 (anti-CD80), GL-1 (anti-CD86), or 14.4.4 (anti-MHC II 
(I-Ed), all purchased from BD Biosciences (Mountain View, CA). The cells were gated based 
on characteristic forward and light scatter to eliminate dead cells and debris from analysis. 
 
Cells lines, plasmids. 293T cells (ATCC) and B16 melanoma were maintained in Dulbecco’s 
Modified Eagle Medium containing 10% heat-inactivated FBS, 1 mM sodium pyruvate and 
0,05 Mm 2-ME. THP-1 and BMDC cells were cultured in RPMI 1640 medium containing 
10% FBS, 1 mM sodium pyruvate, L-glutamine 2 mM, essential amino acids and 0.05 mM 2-
ME. RAW264.7 cells originally obtained from American Type Culture Collection (Rockville, 
MD) were maintained in DMEM medium with 5% FBS and all additives. 
All constructs were generated using a standard PCR-based cloning strategy, and the integrity 
of individual clones was verified through DNA sequencing. To construct C-terminal FLAG-
tagged SIRTs expression vectors, the coding regions were amplified from different DNA 
templates using primer sets containing Flag sequence and cloned into pCMV-SPORT6 
(templates and primers sequences are available in the supplementary data/methods).  
Point mutants of SIRT6-Flag vectors (G52A, H113Y and double mutants G52A/H113Y) and 
SIRT7-Flag vectors (H188Y) were generated by site-directed mutagenesis using a standard 
PCR-based protocol. DNA transfection to 293T cell lines was performed using Lipofectamine 
2000 (Invitrogen), according to the manufacturer’s instructions. Cells were harvested 48h 
after transfection and cells were plated on 96-well plates and cultured for an additional 6h in 
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fresh medium. Culture supernatants were tested for TNF-α and IL-2 content by ELISA. Cells 
were lysed and FLAG-tagged SIRTs expression were analysed by Western blotting or total 
RNA was extracted, and TNF/IL2 mRNA levels were analyzed by quantitative RT-PCR. 
 
Cells lines Culture Assays. RAW264.7 cells were stimulated with LPS 100 ng/ml and were 
treated with the indicated dose of NAm. The culture supernatants were tested for TNF-α 
content by ELISA. THP-1 cells were cultured overnight with increasing doses of APO866, 
and then stimulated with LPS 100 ng/ml for 2h. In the experiments aimed at manipulating the 
intracellular NAD levels, cells were co-incubated with the indicated dose of nicotinic acid 
(NA) and nicotinamide mononucleotide (NMN, both from Sigma). The culture supernatants 
were tested for TNF-α content by ELISA and intracellular NAD levels were measured by an 
enzymatic assay (see below). 
 
NAD and cytokine determinations. Intracellular NAD concentrations were determined by an 
enzymatic cycling assay. Cells were lysed in NAD extraction buffer containing 100 mM 
Na2CO3 and 20 mM NaHCO3. Samples (20µl) were mixed with a cycling buffer (160µl) 
containing 125 mM Tris HCl pH 8.8, 1.25 mM phenazine ethosulfate, 0.625 mM thiazolyl 
blue tetrazolium bromide (MTT), 0.25 mg/ml alcohol dehydrogenase and 1.25 % BSA (all 
from Sigma). The cycling reaction was initiated by adding 20 µl of ethanol 6 M. The samples 
were incubated at 37°C and the optical density at 570 nm was measured after 5, 10, 15 and 20 
minutes using an ELISA plate reader. Serial dilutions of NAD were used as a standard. NAD 
concentrations were normalized to protein concentrations, determined for each sample using 
the micro-BCA kit (Pierce).   
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Cytokines levels in culture media and mouse serum were determined using ELISA kits and/or 
antibody pairs from eBioscience (TNF-α); R&D Systems (Minneapolis, MN) (RANTES) and 
BD Bioscience (IL-2, IL-10, and IL-12).  
 
RNA extraction, Quantitative RT-PCR and Northern blotting. Total cellular RNA was isolated 
from cells with TRIZOL reagent (Invitrogen), according to the manufacturer’s instructions. 
RNA was reverse-transcribed by M-MLV reverse transcriptase, using oligo(dT) primers. 
Specific mRNAs were quantitated by SYBR Green (Eurogentec, Belgium) based RT-PCR 
using ABI Prism 5700 sequence detection system (Applied Biosystems). Primers used for 
quantitative RT-PCR are listed in the supplementary data. The results for TNF quantitative 
RT-PCR assays were normalized to those obtained for the corresponding GaPDH or RPL-32 
mRNA, providing a relative quantification value. For Northern blot, the quality of the RNA 
samples was verified by agarose gel electrophoresis. A measure of 5 µg of total RNA was 
loaded on a 1.5% agarose gel and Northern blot was performed as described 49. Blots were 
hybridized with antisense [α-32P]UTP labelled riboprobes. 
 
TNF mRNA stability.  The effect of NAm on the stability of TNF mRNAs was evaluated using 
the transcriptional inhibitor, actinomycin D (5 µg/ml, Calbiochem). Actinomycin D was 
added 2 h after LPS stimulation with or without NAm. Cells were harvested at various time-
points following actinomycin D treatment, and RNA was isolated. Quantitative RT-PCR was 
performed to determine the levels of TNF mRNAs. The house-keeping gene GAPDH was 
used as internal control.  
 
Polysome analysis. RAW cells stimulated for 2h with 100 ng/ml LPS were washed and 
treated for 30 min with 15 mM NAm. Cells were washed with ice-cold PBS supplemented 
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with cycloheximide (150 µg/ml) and resuspended in polysome extraction buffer (10 mM Tris 
pH 7.2, 140 mM KCl, 10 mM MgCl2, 100 U/ml RNasin, Heparin 0.5 µg/ml, 10 mM 
dithiothreitol, cycloheximide 150 µg/ml, 0.5% NP-40). Nuclei and the majority of 
mitochondria were sedimented by centrifugation for 10 min at 10,000g at 4 °C. Extracts were 
separated over linear sucrose gradients (15%–50% w/w in 25 mM Tris-HCl (pH 7.5), 25 mM 
NaCl, 10 mM MgCl2, Heparin 0.5 µg/ml, cycloheximide 150 µg/ml, 10 mM dithiothreitol) by 
ultracentrifugation. (39,000 rpm for 2 hr at 4 °C in a SW40 swing out rotor). Fractions of 0.5 
ml were collected with continuous monitoring of absorbance at 254 nm. For RNA isolation 
the fractions were mixed in Trizol reagent (Life Technologies Ltd, Paisley, UK), and RNA 
were extracted according to the manufacturer’s protocol. The RNA from each fraction was 
electrophoresed through 1.5 % agarose gels and subjected to Northern blot analysis as 
described above. 
 
Metabolic labelling. Cells were stimulated with LPS (100 ng/ml) for 1h, washed and 
incubated in cysteine- and methionine-free DMEM. 30 min later, the cells were incubated in 
DMEM supplemented with [35S]-labeled cysteine and methionine (Amersham Bioscience), 
brefeldin A (eBioscience) and 15 mM NAm for the indicated time periods, followed by 
immunoprecipitation using polyclonal rabbit anti mouse TNF-α (ImmunoSource, Zoersel, 
Belgium). Immunoprecipitated samples were separated by SDS-PAGE and the gels were 
dried and analyzed by autoradiography after 24h at -80°C 
 
Western blotting. Cells were lysed in radioimmunoprecipitation lysis buffer (RIPA) 
containing protease inhibitors (Roche EDTA-free cocktail), centrifuged for 10 min at 10,000g 
and the insoluble debris were discarded. Samples (2 µg protein) were separated on 10% 
polyacrylamide gels and transferred to a 0.45 µm PVDF membrane (Millipore, Bedford MA). 
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The membrane was blocked with TBS containing 5% BSA, 0.1% Tween-20. FLAG-tagged 
SIRTs were detected using anti-FLAG M2 mAb, while actin was detected using rabbit 
polyclonal antiserum to actin. Bound antibodies were revealed with horseradish peroxidase-
conjugated anti-mouse or protein A by ECL reagent (Amersham Bioscience, Amersham, 




Figure 1. In vivo anti-inflammatory properties of NAm. (A) Naïve C57BL/6 mice were 
injected with LPS (20 mg/kg) or with a combination of a low dose of LPS (5 µg/kg) and D-
galactosamine (0.75 g/kg) or with a combination of TNF (25 µg/kg) and D-galactosamine 
(0.75 g/kg). Survival rates were monitored daily as shown in the left panel, or determined 7 
days post-injection (right panel). (B) Cytokine serum levels were determined by ELISA 90 
min (TNF-α and IL-10) or 120 min (IL-12) following LPS (2 mg/kg) and PBS or NAm 
(500mg/kg) injection as indicated. (C) C57BL/6 mice or IL-10 KO syngenic mice were 
injected as in B. When indicated, mice were treated with a combination of antibodies to IL-10 
(clone JES5-2A5) and to IL-10R (clone 1B1.2). (D) Wt and PARP-1 KO mice were treated as 
indicated in A. Serum TNF-α levels were determined 90 min after LPS injection and shown 
in the left panel. Purified splenic dendritic cells from wt and PARP-1 KO mice were 
stimulated in vitro with CpG (100 ng/ml) and TNF-α levels (right panel) determined in the 
supernatant of 16h cultures.  
 
Figure 2. NAm inhibits TNF-α protein synthesis. (A) RAW 264.7 macrophages were treated 
or not with NAm and stimulated with 100 ng/ml of LPS. Culture media and cells were 
collected 2h after stimulation. TNF-α protein concentration in culture supernatant was 
measured by ELISA while TNF mRNA expression (normalized to GaPDH mRNA) was 
evaluated in cell extracts by quantitative RT-PCR (right panel). RAW264.7 cells were 
stimulated with 100 ng/ml LPS for 2 h. Transcription was then stopped by addition of 5 µg/ml 
actinomycin D (Act D) in the presence of NAm or left untreated. Cells were harvested at the 
time intervals shown, and TNF mRNA levels were quantified by quantitative RT-PCR. 
TNF/GaPDH RNA ratios were plotted as percentages of values at the time of Act D addition 
(left panel). (B) RAW 264.7 cells were stimulated for 2h with 100 ng/ml LPS, washed and 
treated for 30 min with graded doses of NAm. Relative expression of TNF-α protein levels 
(left panel) and mRNA (right panel) were determined respectively by ELISA and northern 
blot analysis. GaPDH mRNA levels were determined as internal control. (C) Polysome profile 
analysis of RAW 264.7 cells treated with 15 mM NAm. Densitrometric quantification of the 
relative RNA northern blot signal intensities across the gradient for TNF-α (left panel) and 
GaPDH (right panel) transcripts. Data are from one of three representative experiments. (D) 
RAW 264.7 cells were stimulated with LPS (100 ng/ml) for 1h, washed and incubated in 
cysteine- and methionine-free DMEM. 30 min later the cells were incubated in DMEM 
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supplemented with [35S]-labeled cysteine and methionine, brefeldin A and with 15 mM NAm 
for the indicated time periods. Immunoprecipitated TNF-α was separated by SDS-PAGE and 
the gels dried and analyzed by autoradiography (NS: not stimulated by LPS). (E) 293T cells 
were co-transfected with plasmid encoding human TNF-α and with a plasmid encoding 
murine IL-2. Secreted cytokines levels were determined in the supernatant of transfected cells 
by ELISA. NAm was found to selectively inhibit the production of hTNF-α.  
 
 
Figure 3. Immunomodulatory properties of NAm on splenic dendritic cells. (A) Purified 
splenic dendritic cells were stimulated with graded doses of CpG in the presence or absence 
of NAm (10mM) and TNF-α and RANTES levels determined in the supernatant of overnight 
cultures. (B) Purified dendritic cells were stained with the indicated antibodies at day 0 
(immature DC, iDC) or after maturation in vitro in the absence (mDC) or in the presence of 
10 mM NAm (mDC + NAm). (C) Splenic dendritic cells were stimulated with 100 ng/ml 
CpG and TNF-α protein concentration in culture supernatants was measured by ELISA while 




Figure 4. Intracellular NAD levels determine TNF-α production capacities. (A) The human 
THP-1 cells line was incubated overnight in the presence of graded doses of the NAmPRT 
inhibitor APO866. Cells were than stimulated with LPS and levels of secreted TNF-α and 
intracellular NAD content determined 2 hours later, as indicated in the method section. (B), 
(C) The experiment was conducted as in (A), except that responder cells were incubated in 
media supplemented with the NAD precursors NA (B) or NMN (C). (D) THP-1 cells were 
incubated overnight in media supplemented with NA at the indicated doses and levels of 
secreted TNF-α and intracellular NAD content evaluated as in (A).  
 
Figure 5. Immunomodulatory properties of sirtuin inhibitors. (A) Purified splenic dendritic 
cells were pretreated with 10 µM of the indicated sirtuin inhibitors and stimulated with graded 
doses of CpG in the continous presence of  inhibitors. TNF-α and RANTES levels determined 
in the supernatant of overnight cultures. Purified dendritic cells were stained with the 
indicated antibodies at day 0 (immature DC, iDC) or after maturation in vitro in the presence 
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of solvent (DMSO mDC) or 10 µM of indicated inhibitors (mDC Cambinol or mDC Sirtinol). 
(B) C57BL/6 mice were injected i.p. with cambinol (100 mg/kg) or its solvent (10%/10% 
ethanol/Cremophore solution) 1 hours before LPS treatment. The figure represents the TNF-α 
and RANTES serum levels of 4 individual mice in each group and is representative of three 
independent experiments.  
 
 
Figure 6. SIRT6 regulates TNF-α protein synthesis. (A) The human cell line 293T was 
transiently transfected with plasmids encoding the indicated tagged forms of murine sirtuin 
members. Protein expression was determined by western blot using an anti-FLAG mAb. (B) 
Pools of 293T cells were transiently transfected with three constructs encoding respectively 
for human TNF-α, mouse IL-2 and a selected murine sirtuin as indicated. The results 
represent the relative content of human TNF-α compared to murine IL-2 released in the 
supernatant during 6 hours of culture. (C) The human cell line 293T was transiently 
transfected with plasmids encoding the indicated tagged forms of wt and mutant forms of 
selected murine sirtuin members. Protein expression was determined as in (A). (D) TNF-α 
translation efficiency of triple transfectants, as described in (B), was determined as detailed in 
the text (mean of two independent experiments). (D) Bone marrow derived dendritic cells 
from wt and SIRT6 KO mice were stimulated with 1 µg/ml CpG and TNF-α protein levels 
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